商品介绍
AZD2281 (olaparib) is phthalazinone-based PARP inhibitor with a potencies of 5 nM and 1 nM for PARP1 and PARP2, respectively. It has been shown to be efficacious in the treatment of breast cancer tumors with BRCA mutations. Specifically, BRCA2 deficient tumor cells showed the strongest differential growth inhibition upon treatment with AZD2281 when compared to BRCA2-proficient cells. [1]AZD2281 has been studied in combination therapies with platinum-based drugs and taxanes; specifically, synergistic toxicity in BRCA2-deficient cells has been shown with cisplatin. [1] AZD2281 has been shown to be a radiosensitizer in the treatment of NSCLC cells. [2]
Technical information:
| Chemical Formula: | | C24H23FN4O3 |
| CAS #: | | 763113-22-0(937799-91-2) |
| Molecular Weight: | | 434.46 |
| Purity: | | > 98% |
| Appearance: | | White |
| Chemical Name: | | 4-(3-(1-(cyclopropanecarbonyl)piperazine-4-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one |
| Solubility: | | Up to 100 mM in DMSO |
| Synonyms: | | AZD2281, AZD-2281, Olaparib, KU-0059436 |
Shipping Condition: The product is shipped in a glass vial at ambient temperature.Storage condition: For longer shelf life, store solid powder at 4oC desiccated, or store DMSO solution at -20oC.
Reference:
| 1. | Evers et al., Selective inhibition of BRCA2-deficient mammary tumor cell growth by AZD2281 and cisplatin. Clin Cancer Res 2008, 14(12), 3916-3925. Pubmed ID:18559613 |
| 2. | Senra et al., Inhibition of PARP-1 by olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft. Mol Cancer Ther. 2011, 10(10), 1949-1958. Pubmed ID:21825006 |
Other Information:
Product Specification (pdf) MSDS (pdf) Certificate of Analysis is available upon request.
品牌介绍
Cellagen Technology 公司位于美国加州San Diego，该公司致力于干细胞相关产品的研发和生产。基于多年为世界*的生物公司提供OEM产品的经验，目前Cellagen Technology公司利用自身优势，拓展了原有产品线，推出了以StemRegenin 1（SR1）为代表的多种自有品牌产品。 NamePriceCat # （Powder）Cat # （10 mM in DMSO）Pathway/Target7,8-Dihydroxyflavone1173C7181-10N/ATrkBA7696622023C2769-10N/AAMPKA83-011513C2831-2C2831-2sTGF-β/ALK4,5,7Abiraterone1853C2247-2C2247-2sP450-CYP17BEZ235833C2392-2C2392-2sPI3K, mTORBIX-012941513C2491-5C2491-5sEpigenetics/G9a HMTCHIR990213553C2447-2C2447-2sGSK3β CP-6905501343C2716-2C2716-2sJAK1,2,3Cyclopamine2193C2925-2C2925-2sHedgehog/SmoDAPT1853C3178-5C3178-5sNotch/γ-secretaseForskolin1853C3677-10N/AAdenylate cyclaseFTY7201173C3897-5C3897-5sS1P receptorsGDC-09411513C4321-5C4321-5sPI3KHh-Ag1.53043C4412-2C4412-2sHedgehog/SmoINCB0184241853C4622-2C4622-2sJAK1/2IWP-31853BackorderBackorderWntKHS1011853C5471-5C5471-5sNeural differentiationLDE2252363C5332-2C5332-2sHedgehog/SmoLDN-1931893723C5361-2C5361-2sBMP/ALK2,3Leukadherin-1#VALUE!C5385-2C5385-2sCD11b, CD18LY2940022193C5929-5C5929-5sPI3KP7C32363C7723-10N/Aneurogenic, neuroprotectivePD03259013723C7303-2C7303-2sMEK1, MEK2PD03329912193C7306-2C7306-2sCdk4, Cdk6PS481343C7748-5C7748-5sPDK1Pyrintegrin3383C7974-1C7974-1sES cell survivalR4062193C7406-2C7406-2sSykR7883723C7788-5C7788-5sSykRapamycin2193C7272-5C7272-5smTORReversine1173C7383-2C7383-2sA3 Adenosine ReceptorRO49290972703C7649-2C7649-2sNotch/γ-secretaseSB4315421513C7243-5C7243-5sTGF-β/ALK4,5,7SF16703723C7316-2C7316-2spTENSitagliptin1513C7482-5C7482-5sDPP-4SRT17202363C7781-2C7781-2sSIRT1StemRegenin1 （SR1）3723C7710-1C7710-1sAryl hydrocarbon receptorSU54022703C7854-1C7854-1sFGFRThiazovivin3553C8442-1C8442-1sROCKUrsolic Acid1853C8776-10N/ASTAT3VX-6801173C8916-10N/AAurora kinaseWnt-C592703C7641-2C7641-2sWntXAV9392703C9289-2C9289-2sWntY-276321853C9127-2C9127-2sROCKhuman Activin A5423P4228-1031910 µg37383P4228-1002199100 µghuman BMP-4 3723P4267-1021910 µg25483P4267-1001499100 µghuman bFGF 3383P4234-5019950 µg23783P4234-5001399500 µgmouse LIF 3383P6543-1019910 µg23783P6543-1001399100 µghuman Wnt-3a 3723P4968-1021910 µg
